Business Law • Business and Commercial Transactions • Administrative Law • Corporate and Securities • Partnerships, Joint Ventures and Other Business Entities • Corporate Governance and General Corporate Matters • Securities Offerings; Corporate and Partnership Finance • Investment Companies, Advisors and Brokers/Dealers • Venture and Private Equity Capital • Mergers, Acquisitions and Divestitures
Business Law Business and Commercial Transactions Administrative Law Corporate and Securities Partnerships, Joint Ventures and Other Business Entities Corporate Governance and General Corporate Matters Securities Offerings; Corporate and Partnership Finance Investment Companies, Advisors and Brokers/Dealers Venture and Private Equity Capital Mergers, Acquisitions and Divestitures
ISLN:
904884188
Admitted:
1954
University:
Pomona College, A.B., 1951
Law School:
University of Oklahoma, LL.B.; University of Oklahoma, LL.B.; University of Oklahoma, LL.B.
Name / Title
Company / Classification
Phones & Addresses
John L. Mee Director, President
Future Life Institute Inc Noncommercial Research Organization
5491 SE Schooner Oaks Way, Stuart, FL 34997
John F. Mee Manager
Aardvark Holdings, LLC
John L. Mee Treasurer, Director, Secretary
Power Talent Network Inc Internet · Data Processing/Preparation
PO Box 937, Boca Raton, FL 33429 5491 SE Schooner Oaks Way, Stuart, FL 34997
John L. Mee Manager, Vice President
Jamber, LLC
411 N New Riv Dr E, Fort Lauderdale, FL 33301
John Mee Manager
MYLIVINGLEGACY LLC Nonclassifiable Establishments
5491 SE Schooner Oaks Way, Stuart, FL 34997
Us Patents
Methods For Sustainable Human Cognitive Enhancement
- Petaluma CA, US John Lawrence Mee - Stuart FL, US
Assignee:
Cognigenics, Inc. - Petaluma CA
International Classification:
A61K 47/69 A61K 31/713 A61K 38/46
Abstract:
A method of achieving sustainable, general-purpose cognitive enhancement comprising administering a gene-editing endonuclease complexed with a neuron-targeting vector and a synthetic guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain.
Method For Treating Neurological Conditions And Improving Human Cognition
A method of treating neurological conditions and improving human cognition by modifying neurons in targeted brain regions, comprising administering a neuron editing biologic in combination with a brain region activator which directs the biologic to a specific area in the brain.
Reversible Method For Sustainable Human Cognitive Enhancement
A reversible method for general-purpose cognitive enhancement in mentally healthy adults comprising administering an RNA-editing ribonuclease complexed with a single guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain.
Adjustable Method For Sustainable Human Cognitive Enhancement
A method of achieving sustainable, general-purpose cognitive enhancement in mentally-healthy adults comprising administering a gene-editing endonuclease complexed with a gene-expression inhibiting nucleotide and a synthetic guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain.
Method For Sustainable Human Cognitive Enhancement
A method of achieving sustainable, general-purpose cognitive enhancement in mentally-healthy adults comprising administering a gene-editing endonuclease complexed with a synthetic guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain.